Halozyme (HALO) Q1 2026 earnings review
Strategic M&A Stokes $1B Buyback Confidence
Halozyme delivered an exceptionally strong Q1 2026, with total revenue accelerating 42% YoY to $376.7 million, powered by a 43% surge in high-margin royalty revenue. The quarter validated the company's aggressive M&A strategy: recent acquisitions of Elektrofi (Hypercon) and Surf Bio generated immediate commercial momentum, securing three new multi-target licensing deals with Vertex, Oruka, and GSK. Backed by expanding profitability and robust cash generation, management announced a massive $1 billion share repurchase authorization, targeting at least $400 million in 2026. The guidance remains rock solid, projecting FY26 revenue of $1.71B-$1.81B and non-GAAP EPS growth nearing 100%.
🐂 Bull Case
The addition of Hypercon and Surf Bio transforms Halozyme into a 'one-stop shop' for subcutaneous delivery. Signing three new deals (Vertex, Oruka, GSK) in a single quarter proves intense biopharma demand for high-concentration, at-home delivery solutions.
The new global collaboration with GSK represents ENHANZE's first application in Antibody-Drug Conjugates (ADCs). If successful, this opens a massive, entirely new therapeutic modality for future royalty generation.
🐻 Bear Case
Operating expenses are inflating rapidly. SG&A jumped 36% YoY to $57.9M, burdened by integration costs and ongoing patent infringement litigation against Merck. R&D surged 73% following the acquisitions.
Despite massive YoY gains, total revenue and royalties declined sequentially from 25Q4. While management previously flagged Q1 contractual resets as the cause, it highlights the lumpiness and partner-dependency of the financial model.
⚖️ Verdict: 🟢
Bullish. The core ENHANZE franchise is generating immense cash flow, seamlessly funding aggressive M&A and a mammoth $1B buyback without impairing the balance sheet. The rapid commercial validation of the newly acquired Hypercon technology significantly de-risks the company's long-term growth narrative.
Key Themes
Hypercon Monetization Accelerating
Halozyme's Q4 2025 acquisition of Elektrofi (Hypercon) is paying immediate dividends. The company signed two exclusive global collaboration agreements with Vertex and Oruka Therapeutics for up to five targets combined. This dramatically expands Halozyme's footprint into the at-home, high-concentration auto-injector market, creating a new wave of royalty opportunities projected to launch in the early 2030s.
ENHANZE Breakthrough in ADCs
The new multi-target agreement with GSK marks the first potential application of ENHANZE for Antibody-Drug Conjugates (ADCs). ADCs are one of oncology's fastest-growing modalities, but they often suffer from dose-limiting toxicities. Preclinical data showing ENHANZE can lower peak concentrations (Cmax) by 60-75% while maintaining efficacy gives Halozyme a profound new growth vector.
Core Blockbusters Expand Addressable Markets
The core ENHANZE royalty engine is Stable and robust. argenx secured FDA approval for VYVGART Hytrulo in all serotypes of generalized myasthenia gravis (gMG) and posted positive Phase 3 data in ocular MG (adding ~7,000 U.S. patients). Meanwhile, Janssen's DARZALEX Faspro gained its 12th and 13th approved indications, pushing deeper into newly diagnosed multiple myeloma—the longest-duration treatment setting.
Aggressive Capital Return Strategy
With the balance sheet reinforced by cash generated from operations, the Board approved a new $1 billion share repurchase program extending through 2028. By committing to buy back at least $400 million in 2026 alone, management is aggressively capitalizing on perceived valuation disconnects while comfortably absorbing the ~$360 million upfront costs from the recent Surf Bio and Elektrofi acquisitions.
Litigation and Integration Bloat SG&A
Selling, general, and administrative expenses are Accelerating, rising 36% YoY to $57.9 million. This was driven by a combination of higher compensation, integration costs for Elektrofi and Surf Bio, and ongoing intellectual property litigation against Merck over subcutaneous Keytruda. While adjusted EBITDA excludes $11.2 million of these litigation costs, the actual cash drain from legal battles remains a persistent headwind.
Sequential Revenue Lumpiness Contradicts Hyper-Growth Narrative
While YoY growth metrics look stellar (+42%), total revenue Decelerated sharply on a sequential basis, falling from $451.8M in 25Q4 to $376.7M in 26Q1. Royalty revenues similarly dropped from $258.0M to $240.7M. Although management previously telegraphed this Q1 seasonality due to contractual royalty tier resets and back-half weighted milestones, this dynamic forces investors to underwrite significant H2 execution risk.
Other KPIs
Reversing. Net income flipped from a steep -$141.6M GAAP loss in 25Q4 (driven by a $284.9M acquired in-process R&D charge for Surf Bio) to a robust $150.0M profit in 26Q1. This represents a 27% YoY increase from 25Q1, proving the core business remains highly profitable once one-time acquisition charges are stripped away.
Accelerating. Up 42% YoY from $162.0 million. The company successfully absorbed the operational overhead of two new acquisitions while drastically improving profitability, demonstrating the extreme operating leverage embedded in the royalty-driven business model.
Accelerating. Increased 64% YoY from $48.4 million in 25Q1. Management attributed this outsized growth to an increase in bulk rHuPH20 sales to partners. While this drives top-line revenue, it carries significantly lower margins than pure royalty streams, marginally weighing on gross margins.
Guidance
Stable. The company reiterated its aggressive full-year outlook, implying a massive 22% to 30% YoY growth rate over FY25's $1.396 billion. This relies heavily on API sales and back-half weighted milestones.
Stable. The reiterated 30% to 35% YoY growth projection pushes royalty revenue well past the $1 billion milestone. This requires sustained subcutaneous conversion momentum for DARZALEX Faspro, Phesgo, and VYVGART Hytrulo.
Accelerating. Implies 71% to 83% YoY growth. Crucially, management noted this guidance explicitly absorbs approximately $60 million in new investments directed toward the integration and scale-up of the Hypercon and Surf Bio technologies.
Accelerating. Represents 87% to 99% growth over FY25. Management highlighted that this EPS guidance does not even factor in the accretive effects of the newly announced $1 billion share repurchase program, suggesting potential upside to this range.
Key Questions
ADC Development Timelines
With the landmark GSK deal validating ENHANZE for Antibody-Drug Conjugates, what is the expected clinical timeline for the first ADC programs, and how do the economics differ from standard monoclonal antibody deals?
Hypercon vs ENHANZE Cannibalization
Now that you've signed three rapid deals for Hypercon, are you seeing any cannibalization of the traditional ENHANZE pipeline, or are partners strictly segmenting these technologies by volume and treatment setting?
Litigation Spend Run-Rate
With $11.2 million excluded from Q1 EBITDA due to IP litigation costs against Merck, should investors view this as the normalized quarterly run-rate until the expected PGR decisions in 2026?
Impact of 26Q1 Sequential Contraction
Given the sequential decline in Q1 royalty revenue, how steep of a ramp is required in H2 2026 to hit the $1.15 billion midpoint, and what specific partner product milestones drive that inflection?